Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free
source: pixabay.com

Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free

  The initial CRISPR treatment for sickle cell disease was administered to Victoria Gray in July 2019. Victoria, a resident of Forest, Mississippi, was born with sickle cell and has…

Continue Reading Patients Who Received CRISPR Gene Editing for Beta Thalassemia and Sickle Cell Disease Remain Pain Free
Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay
source: pixabay.com

Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay

As reported in PR NewsWire;  in an effort to help the entirety of the sickle cell disease community, Emmaus Life Sciences, Inc has announced a program that will provide their…

Continue Reading Emmaus Life Sciences Makes Drug For Sickle Cell Disease Free For Those That Can’t Pay

A CRISPR Tool With the Potential to Halt the Progression of Sickle Cell and Beta Thalassemia

According to an NBC AP news item, early results show that CRISPR, a “tool” that alters DNA permanently in blood cells, has the potential to not only stop the progression…

Continue Reading A CRISPR Tool With the Potential to Halt the Progression of Sickle Cell and Beta Thalassemia
Use of Tissue Type Plasminogen Activator in Sickle Cell Disease Patients Experiencing Stroke
source: pixabay.com

Use of Tissue Type Plasminogen Activator in Sickle Cell Disease Patients Experiencing Stroke

by Lauren Taylor from In The Cloud Copy Sickle cell disease or SCD is a type of red blood cell disorder in which the normally round red blood cells are…

Continue Reading Use of Tissue Type Plasminogen Activator in Sickle Cell Disease Patients Experiencing Stroke
Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU
source: pixabay.com

Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU

According to a story from Street Insider, the biopharmaceutical company Forma Therapeutics Holdings, Inc., recently announced that its investigational therapy candidate FT-4202 has earned Orphan Drug designation from the European…

Continue Reading Experimental Treatment for Sickle Cell Disease Earns Orphan Drug Designation in the EU
Now Available: FTX-6058 Proof-of-Concept Data for SCD, Beta Thalassemia
source: pixabay.com

Now Available: FTX-6058 Proof-of-Concept Data for SCD, Beta Thalassemia

For years, clinical-stage biopharmaceutical company Fulcrum Therapeutics ("Fulcrum") has worked to develop therapies for patients with rare genetic disorders and diseases. Somewhat recently, their focus was on treating beta thalassemia…

Continue Reading Now Available: FTX-6058 Proof-of-Concept Data for SCD, Beta Thalassemia
EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
source: pixabay.com

EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment

CRISPR Therapeutics, in combination with Vertex Pharmaceuticals, has recently announced that the European Medicines Agency (EMA) has granted the Priority Medicines (PRIME) designation for their sickle cell disease (SCD) treatment,…

Continue Reading EMA Grants PRIME Designation to CTX001, a Sickle Cell Disease Treatment
The Impact of COVID-19 on Patients with Thalassemia and Sickle Cell Disease: A Webinar Review
source: pixabay.com

The Impact of COVID-19 on Patients with Thalassemia and Sickle Cell Disease: A Webinar Review

  As COVID-19 continues to spread across the globe, more and more people are wondering how this virus might affect them. This is especially true for patients with rare diseases,…

Continue Reading The Impact of COVID-19 on Patients with Thalassemia and Sickle Cell Disease: A Webinar Review